Alka Batycky - May 30, 2023 Form 4 Insider Report for Landos Biopharma, Inc. (LABP)

Role
Director
Signature
/s/ Gregory Oakes, attorney-in-fact
Stock symbol
LABP
Transactions as of
May 30, 2023
Transactions value $
$0
Form type
4
Date filed
6/1/2023, 04:21 PM
Next filing
May 23, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Stock Option (right to buy) Award $0 +3.6K $0.00 3.6K May 30, 2023 Common Stock 3.6K $3.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the option will vest and become exercisable in 36 equal monthly installments beginning on May 30, 2023, subject to the Reporting Person's continuous service with the Issuer on each such date.